(1) McKenney JM, et al. A randomized, double-blind, placebo-controlled trial of the
safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin
type 9 serine protease, REGN727/SAR236553, in patients with primary
hypercholesterolemia. Presented at the 61st ACC Annual Meeting, Chicago, IL, USA; March
26, 2012. Abstract No. #306-10.
(2) Roth E, et al. The effects of co-administering a monoclonal antibody to proprotein
convertase subtilisin/kexin 9, REGN727/SAR236553, with 10 and 80 mg atorvastatin
compared to 80 mg alone in patients with primary hypercholesterolemia. Presented at the
61st ACC Annual Meeting, Chicago, IL, USA; March 26, 2012. Abstract No. #911-5.
(3) Seidah NG, et al. The secretory proprotein convertase neural apoptosis-regulated
convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. PNAS 2003;100
:928-33.
(4) Park SW, et al. Post-transcriptional regulation of low density lipoprotein receptor
protein by proprotein convertase subtilisin/kexin Type 9a in mouse liver. J Biol Chem
2004;279:50630-8.
(5) Cohen JC et al. Sequence variations in PCSK9, low LDL, and protection against
coronary heart disease. N Engl J Med 2006;354:1264-72.
(6) Long-Term Safety and Tolerability of SAR236553 (REGN727) in High Cardiovascular
Risk Patients With Hypercholesterolemia. Available at:
http://www.clinicaltrials.gov/ct2/show/N.... Last accessed 9 Feb 2012.
(7) Farnier M. The role of proprotein convertase subtilisin/kexin type 9 in
hyperlipidemia: focus on therapeutic implications. Am J Cardiovasc Drugs
2011;11:145-52.
CONTACT: Sanofi: Media Relations: Marisol Peron, Tel:+33-(0)-1-53-77-45-02, Mobile: +33-(0)-6-08-18-94-78,marisol.peron@sanofi.com; Investor Relations: Sebastien Martel,+33-(0)1-53-77-45-45, IR@sanofi.com; or Regeneron: Media Relations: PeterDworkin, +1-914-847-7640, peter.dworkin@regeneron.com; Investor Relations:Michael Aberman, M.D., +1-914-847-7799, michael.aberman@regeneron.com
